HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Eligibility Recertification 

Percentage of ADAP enrollees1 who are reviewed for continued ADAP eligibility2 two or more times in the 

measurement year. 

Numerator: Number of ADAP enrollees who are reviewed for continued ADAP eligibility2

 at least 

two or more times which are at least 150 days apart in the measurement year. 

Denominator: Number of clients enrolled in ADAP3

 in the measurement year. 

Patient 

Exclusions: 

1. Clients approved for new ADAP enrollment in the measurement year. 

2. Clients terminated from ADAP in the first 180 days of the measurement year. 

Data Element: 

1. Was the client enrolled in ADAP during the measurement year? (Y/N) 

a. If yes, was the client reviewed for continued ADAP eligibility1

 two or more 

times at least 150 days apart during the measurement year? (Y/N) 

i. If yes, list the dates of review. 

Data Sources:  AIDS Drug Assistance Program Quarterly Data Report, Section 2: Annual 

Submission 

National Goals, 

Targets, or 

Benchmarks for 

Comparison: 

Part B Collaborative4: 92% 

Basis for Selection: 

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415)5 requires that the Ryan White 

HIV/AIDS Program be the payor of last resort. HAB Policy 07-03 specifies that “grantees must be capable 

of providing the HAB with documentation related to the use of funds as payor of last resort and the 

coordination of such funds with other local, State and Federal funds.6” 

US Public Health Service Guidelines: 

This measure addresses the intent of HHS Treatment Guidelines for the use of antiretroviral agents and the 

prevention and treatment of opportunistic infections in HIV infected individuals.7 - 11 

References/Notes: 

1 Includes all individuals, regardless of age. 

2 “Review for continued ADAP enrollment” (recertification) is a process for “confirming that a client receiving ADAPfunded services is still eligible to receive those services.” Verification of ADAP eligibility includes verification of third 

party payor sources, such as Medicaid and Medicare. [Source: “Instructions for Completing The Drug Assistance 

Program Quarterly Data Report”. Available at 

ftp://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20_Feb%2022_08_.pdf, page 20. Accessed July 17, 2009.] 

3

Clients enrolled in ADAP: Refers to “the total number of individuals who are enrolled or certified as eligible to 

receive medications in...ADAP, regardless of whether they used ADAP services. [Source: “Instructions for 

Completing The Drug Assistance Program Quarterly Data Report”. Available at 

ADAP Final |December 10, 2009 | Page 3 of 9 
 

HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Eligibility Recertification 

ftp://ftp.hrsa.gov/hab/ADAP%20Instructions_Final%20_Feb%2022_08_.pdf. Accessed July 17, 2009.] 

4 Part B Collaborative measure reads: “Percent of ADAP enrollees recertified for ADAP eligibility criteria at least 

annually”. 

5

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a). 

6

HRSA/HAB, Policy Notice-07-03, “The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS 

Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services”, September 2007. 

7 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 

2009; 1-161.. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 

December 7, 2009. 

8 Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 

Use of Antiretroviral Agents in Pediatric HIV Infection. February 23, 2009; pp 47. Available at 

http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed September 9, 2009. 

9 Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of 

Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce 

Perinatal HIV Transmission in the United States. April 29, 2009; pp 1-90. Available at 

http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed September 9, 2009. 

10 Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in 

HIV-Infected Adults and Adolescents. MMWR 2009;58(No. RR-4): 1-216. Available at: 

http://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf. Accessed September 9, 2009. 

11 Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections 

Among HIV-Exposed and HIV-Infected Children. MMWR 2009;58(No. RR-11): 1-176. Available at: 

http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf. Accessed September 9, 2009. 

ADAP Final |December 10, 2009 | Page 4 of 9